The companies will use the AI-based platform to accelerate cancer drug discovery. Credit: sanjeri via Getty Images. AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a ...

The platform enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes. Credit: THICHA SATAPITANON / Shutterstock. Repertoire Immune Medicines ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that topped Wednesday’s trading. Wall Street’s major indices rebounded anew on ...

Investing.com -- Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc. The ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI. The technology company said the ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI (Nasdaq: TEM) and D-Wave Quantum (NYSE: QBTS) are up by double-digit percentages today while Rigetti Computing (Nasdaq: RGTI) is enjoying a nice pop amid signs AI and the quantum ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...